New Alzheimer's drug approved in Brazil by Anvisa

The National Health Surveillance Agency (Anvisa) approved, in April 2025, a new Alzheimer's drug which promises to change the treatment scenario for the disease in Brazil. The drug, called Donanemabe, will be marketed under the name Kisunla and its main function is to slow the progression of Alzheimer's in the early stages.

What is Donanemabe?

O Donanemabe is a monoclonal antibody developed to remove beta-amyloid plaques in the brain, which are characteristic of Alzheimer's disease. In addition, international clinical studies have proven that the drug is capable of reduce the progression of the disease, This improves the quality of life of patients during the first years of diagnosis.

How does the Alzheimer's drug work in the body?

Donanemabe's mechanism of action is focused on removal of beta-amyloid plaques in the brain. However, these plaques are toxic protein deposits that interfere with communication between neurons and accelerate cognitive degeneration.

According to Anvisa, the release of the drug is based on robust scientific evidence that demonstrates, for example:

• Significant reduction in disease progression in the early stages
• Improved cognition and functionality tests
• Clinical safety with continuous monitoring of adverse effects

Who can use the Alzheimer's drug?

The medicine is indicated exclusively for patients diagnosed with early-stage Alzheimer's, The use of the drug is subject to medical prescription and neurological monitoring. For this reason, use will be restricted and guided by specific clinical protocols defined by Anvisa.

When will it be available in Brazil?

With the registration approved, the expectation is that the Kisunla (Donanemabe) will reach pharmacies and specialized clinics in the coming months, after the pricing and distribution stage. In addition, the drug represents a new hope for relatives and patients who face the challenges of Alzheimer's in the country.

Why is this approval so important?

The approval of a drug for Alzheimer's prevention is extremely important, for example:

• Innovation in treatmentThis is the first drug approved in Brazil with this mechanism of action.
• Impact on public healthAlzheimer's is one of the main causes of dementia in the country.
• Quality of lifeThis is because it slows down the effects of the disease during a critical period of diagnosis.
• Scientific progress: A drug that can prevent Alzheimer's validates new theories about the causes of the disease

FIC Company

Whether it's for the procurement of highly complex medicines or the logistics management of pharmaceutical supplies, FIC Company is the right choice. With a global supply network, a commitment to safety and expertise in the sector, we guarantee innovative solutions for your business needs.

With an approach based on supply chain technology and optimization, we connect your company to a global networking, facilitating processes and boosting results.

Do you need to optimize project and research logistics? Fale com nossos especialistas e descubra como podemos simplificar suas operações com soluções personalizadas. 🚀